Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
It is important to stress that this procedure must be done under the supervision of a trained, certified doctor
Ianalumab, a fully human monoclonal antibody targeting BAFF-R, is under investigation in a randomized, double-blind phase III trial to assess its efficacy and safety in SLE patients (ClinicalTrials.gov Identifier: NCT05624749) (137)
What target should we choose next, what modality, which indication, and crucially, how do we measure the effect on aging using reliable aging clocks
29 GIP Agonism as a Potential Therapeutic Approach for Atherosclerotic Cardiovascular Disease The cardioprotective actions of incretin-based agents, particularly the GLP-1RAs, have a bulk of supporting evidence in the form of clinical studies
US$ 24.72
US$ 27.53
US$ 21.42
US$ 24.01
US$ 27.66
US$ 29.62
US$ 27.69
